These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 8017410)
1. Cefepime: part of the new generation. Rybak MJ; Palmer SM Am J Hosp Pharm; 1994 Feb; 51(4):459-60. PubMed ID: 8017410 [No Abstract] [Full Text] [Related]
7. Cephalosporin group of antimicrobial drugs. Thomson TD; Quay JF; Webber JA J Am Vet Med Assoc; 1984 Nov; 185(10):1109-14. PubMed ID: 6392238 [No Abstract] [Full Text] [Related]
8. What's new in antibiotic resistance? Focus on beta-lactamases. Babic M; Hujer AM; Bonomo RA Drug Resist Updat; 2006 Jun; 9(3):142-56. PubMed ID: 16899402 [TBL] [Abstract][Full Text] [Related]
9. The third generation cephalosporins. Farber B; Moellering RC Bull N Y Acad Med; 1982 Nov; 58(8):696-710. PubMed ID: 6762896 [No Abstract] [Full Text] [Related]
10. [A choice of antibacterial chemotherapy for nosocomial infections caused by pathogens producing broad-spectrum beta-lactamases]. Beloborodov VB Antibiot Khimioter; 2001; 46(12):3-7. PubMed ID: 12108091 [No Abstract] [Full Text] [Related]
12. In vitro and in vivo antibacterial activity of cefoperazone. Mitsuhashi S; Minami S; Matsubara N; Yotsuji A; Kurashige S; Saikawa I Clin Ther; 1980; 3(Spec Issue):1-13. PubMed ID: 6446381 [No Abstract] [Full Text] [Related]
13. In vitro and in vivo microbiological evaluations of cefoperazone. Renzini G; Ravagnan G; Piccolomini R; Dainelli B; Comanducci A Clin Ther; 1980; 3(Spec Issue):139-44. PubMed ID: 6446388 [No Abstract] [Full Text] [Related]
14. [General considerations on the clinical use of cephalosporins]. Varese LA; Grazioli FT Minerva Pediatr; 1977 Feb; 29(3):183-214. PubMed ID: 846468 [No Abstract] [Full Text] [Related]
15. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases]. Bedenić B Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890 [TBL] [Abstract][Full Text] [Related]
16. [Clinico-microbiologic bases for the use of new cephalosporins]. De Bac C; Mascellino MT; Nuti M Minerva Med; 1982 Apr; 73(15):899-903. PubMed ID: 6979006 [No Abstract] [Full Text] [Related]
17. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Sanders WE; Sanders CC Rev Infect Dis; 1988; 10(4):830-8. PubMed ID: 3055176 [TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory studies of a new cephalosporin derivative--cefathiamidine. Tze-ying T; Fu W; Chih-lin C; Mei-fang C; Ching-teh C; Ying-yuan C; Yu-kun L Chin Med J (Engl); 1979 Jan; 92(1):26-36. PubMed ID: 105842 [No Abstract] [Full Text] [Related]
19. [Cephalosporins of the 1980s. New aminothiazolyloxyimino-cephalosporins and their sulfoxides]. Nazarov AD; Zhelaev AA Antibiot Khimioter; 1990 Jan; 35(1):44-8. PubMed ID: 2185710 [No Abstract] [Full Text] [Related]
20. Penicillins and cephalosporins: antimicrobial and pharmacological properties. Wise R Lancet; 1982 Jul; 2(8290):140-3. PubMed ID: 6123849 [No Abstract] [Full Text] [Related] [Next] [New Search]